Hey Dr Charlie! Thanks for the Atomic IBD Uncut series, very useful! I'm a 28 yo ileal Crohn's patient from another country who has the HLA-DQ2.5 phenotype. I have been managing my Crohn's with strict dietary therapy mixed with occasional EEN-s and regular calpro monitoring since my diagnosis 18 months ago with relative success. My doc wants me on a Humira biosimilar, and I also wouldnt't mind getting my social life back, but I have read many studies about how my phenotype will make secondary treatment failure very likely. I have also seen that after such a failure other drugs will be less likely to work afterwards. I have sent my doubts to my doc a few months ago but so far no response. In a month I will have to go back and decide but I am very reluctant unless we are going to do proactive drug monitoring / escalation, which I have read has a good chance of preventing the treatment failure in my case. Not asking for medical advice but would you mind sharing your view whether my approach makes sense, and whether this proactive drug monitoring is a common thing in Europe and is it reasonable for me to expect it? In case its not a possibility for me, but its common or expected to be common in clinical practice elsewhere, then I wouldn't want to exhaust this treatment option here, well, at least until I am able to keep my disease more or less in control without it. Thanks in advance if you can share your view!
Ive had an adverse reaction to Azathioprine Infliximab caused Demyelinating disease Primary none responder to Vedolizumab Just going to start ustekinumab So this is fantastic news as im fast running out of meds
Update in the rain. That's how dedicated this man is!
Hey Dr Charlie! Thanks for the Atomic IBD Uncut series, very useful! I'm a 28 yo ileal Crohn's patient from another country who has the HLA-DQ2.5 phenotype. I have been managing my Crohn's with strict dietary therapy mixed with occasional EEN-s and regular calpro monitoring since my diagnosis 18 months ago with relative success. My doc wants me on a Humira biosimilar, and I also wouldnt't mind getting my social life back, but I have read many studies about how my phenotype will make secondary treatment failure very likely. I have also seen that after such a failure other drugs will be less likely to work afterwards. I have sent my doubts to my doc a few months ago but so far no response. In a month I will have to go back and decide but I am very reluctant unless we are going to do proactive drug monitoring / escalation, which I have read has a good chance of preventing the treatment failure in my case. Not asking for medical advice but would you mind sharing your view whether my approach makes sense, and whether this proactive drug monitoring is a common thing in Europe and is it reasonable for me to expect it? In case its not a possibility for me, but its common or expected to be common in clinical practice elsewhere, then I wouldn't want to exhaust this treatment option here, well, at least until I am able to keep my disease more or less in control without it. Thanks in advance if you can share your view!
more specifically i am talking about my HLA-DQA1*05 allele
I brought this very idea up at a St Marks meeting 2/3 yrs ago and got aggressively put down at the very thought of ACT 😮
Ive had an adverse reaction to Azathioprine
Infliximab caused Demyelinating disease
Primary none responder to Vedolizumab
Just going to start ustekinumab
So this is fantastic news as im fast running out of meds
Three therapy together is dangerous. 8:18
Why is it necessary to talk about IBD in the pouring rain?
Also the two watches? Why not wear two glasses next time?